Each tablet provides L-methyl Folate 400mcg. Because L-methylfolate is the active form of folic acid, it is readily available for absorption and exhibits a faster onset of action. Large numbers of people (almost 20-40%) have a MTHFR (methylenetetrahydrofolatereductase "MTHFR" polymorphism) genotype variation and are unable to fully convert regular folic acid to L-methylfolate, leading to folic acid associated deficiency symptoms. Supplementation with folic acid is internationally recommended to women from the moment they are trying to conceive until 12 weeks of pregnancy or can be continued towards the end of pregnancy as per physician’s recommendations.